Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection

• Published in: AIDS (London) Vol. 15; no. 15; pp. 1985 - 1991
• Main Authors: NIEUWKERK, Pythia T, GISOLF, Elisabeth H, REIJERS, Monique H. E, LANGE, Joep M. A, DANNER, Sven A, SPRANGERS, Mirjam A. G
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 19.10.2001
• Subjects: Adult; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - therapeutic use; Antibiotics. Antiinfectious agents. Antiparasitic agents; antiretroviral therapy; Antiretroviral Therapy, Highly Active; Antiviral agents; Biological and medical sciences; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections - drug therapy; HIV Infections - virology; HIV-1 - drug effects; HIV-1 - physiology; Human immunodeficiency virus 1; Human viral diseases; Humans; Infectious diseases; Male; Medical sciences; Middle Aged; nelfinavir; Pharmacology. Drug treatments; Quality of Life; Reverse Transcriptase Inhibitors - administration & dosage; Reverse Transcriptase Inhibitors - therapeutic use; RNA, Viral - blood; Time Factors; Treatment Outcome; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Viral Load; Purine nucleoside; Prognosis; RNA-directed DNA polymerase; HIV-1 virus; Ritonavir; Stavudine; Saquinavir; Reverse transcriptase inhibitor; Nelfinavir; Antiviral; Pyrimidine nucleoside; Human; Immunopathology; Drug combination; Enzyme; Transferases; Retroviridae; Enzyme inhibitor; Lamivudine; AIDS; Immune deficiency; Lentivirus; Long term; Quality of life; Infection; Virus; Peptidases; Nucleotidyltransferases; Chemotherapy; Treatment; Viral disease; Dideoxynucleoside; Hydrolases; Human immunodeficiency virus; Didanosine; Therapeutic protocol; Zidovudine; Comparative study; Protease inhibitor
• ISSN: 0269-9370; 1473-5571
• DOI: 10.1097/00002030-200110190-00011

To compare changes in quality of life (QoL) over 96 weeks in patients enrolled in a triple-therapy protocol, a treatment-intensification protocol, or an induction-maintenance therapy protocol, and to compare QoL between patients who continued and discontinued their antiretroviral regimen. Naive patients enrolled in a triple-therapy protocol (zidovudine/lamivudine or stavudine/didanosine or stavudine/lamivudine supplemented with protease inhibitor therapy of choice) (n = 35), a protocol of treatment intensification (ritonavir/saquinavir or ritonavir/saquinavir/stavudine) (n = 74) in which therapy was intensified with nucleoside analogue(s) in cases of insufficient viral suppression, and a protocol of induction (saquinavir/nelfinavir/lamivudine/ stavudine) maintenance (saquinavir/nelfinavir or stavudine/nelfinavir) therapy (n = 50). Changes from baseline in QoL assessed by the Medical Outcomes Study HIV Health Survey at weeks 0, 12, 24, 36, 48, 72 and 96. Patients in the triple-therapy and treatment-intensification protocols showed more favourable changes in physical function, social function, mental health, energy/fatigue, health distress and overall QoL compared to patients in the induction-maintenance protocol, with patients in the first two protocols showing improvements in QoL and those in the induction-maintenance protocol showing declining or unchanged QoL. Patients who discontinued study medication due to insufficient efficacy, toxicities or at their own request showed less favourable changes in QoL compared with patients who continued their regimen. The highest proportion of discontinuations was within the induction-maintenance protocol. Antiretroviral treatment strategies that are effective and tolerable have the potential to improve patients' QoL over 96 weeks.